Lineage Cell Therapeutics (LCTX) Construction in Progress (2014 - 2019)

Lineage Cell Therapeutics has reported Construction in Progress for 6 years, with the latest figure at $8.9 million in Q1 2019.

• For the quarter ending Q1 2019, Construction in Progress changed N/A year-over-year to $8.9 million; the trailing twelve-month figure through Mar 2019 stood at $8.9 million (changed N/A YoY), and the FY2018 full-year result was $1.3 million, down 77.08% from the prior year.
• Construction in Progress for Q1 2019 stood at $8.9 million, up from $1.3 million in the prior quarter.
• The five-year high for Construction in Progress was $8.9 million in Q1 2019, with the low at $93000.0 in Q4 2015.
• Historically, Construction in Progress has averaged $3.1 million across 5 years, with a median of $1.6 million in 2016.
• Annual changes were most pronounced in 2015 — Construction in Progress sank 77.09% — and 2016, when it soared 117.26%.
• Lineage Cell Therapeutics' Construction in Progress stood at $93000.0 in 2015, then surged by 1620.43% to $1.6 million in 2016, then jumped by 245.81% to $5.5 million in 2017, then plunged by 77.08% to $1.3 million in 2018, then soared by 603.31% to $8.9 million in 2019.
• The last three Construction in Progress figures came in at $8.9 million (Q1 2019), $1.3 million (Q4 2018), and $5.1 million (Q3 2018), per Business Quant data.